29,670 Results

Real world analysis of Invokana in type 2 diabetes published in Circulation.- Janssen Pharma.

 Added 13 hours ago

A new real-world analysis of adults with type 2 diabetes and established cardiovascular disease (CVD) shows adult patients who initiated...

Subgroup analysis of FLAURA data of Tagrisso in NSCLC shows specific patient group benefits.- AstraZeneca.

 Added 13 hours ago

AstraZeneca presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored Tagrisso (osimertinib) as 1st-line...

Global AF Awareness Week 2017

 Added 13 hours ago

Global AF Awareness Week 2017

Today starts the Awareness Week for Atrial Fibrillation.

Two analyses show benefits of Xarelto for patients with PAD and CAD.- Bayer + Janssen.

 Added 1 day ago

Two new analyses of data from the COMPASS trial show that Xarelto (rivaroxaban),from Bayer and Janssen ,significantly cut the amputation...

Acorda Therapeutics increases blood cell monitoring in Phase III programme for tozadenant for Parkinson’s disease.

 Added 1 day ago

Acorda Therapeutics, Inc. announced that it has increased the frequency of blood cell count monitoring for participants to weekly in...

FDA approves remote programming via telemedicine of Nucleus Cochlear Implant System.- Cochlear Corporation.

 Added 1 day ago

The FDA has approved a remote feature for follow-up programming sessions for the Nucleus Cochlear Implant System, from Cochlear Corporation,...

FDA approves Sutent to treat high risk patients post surgery with renal cell carcinoma

 Added 2 days ago

The FDA has approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

Schizophrenia relapse, patient considerations, and potential role of lurasidone.

When treating persons with schizophrenia, delaying time to relapse is a main goal. Antipsychotic medication has been the primary treatment approach, and there are a variety of different choices available.

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records.

Background: Severe and persistent mental illnesses, such as schizophrenia and bipolar disorder, are associated with increased risk of obesity compared to the general population. While the association of lurasidone and lower risk...

Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation?

Dopamine agonists have been associated with an increased risk of developing impulse control disorders (ICDs). The US Food and Drug Administration (FDA) issued a safety warning in 2016 of a possible association between ICDs and aripiprazole.

Load more